CB
This company provides a tumor-based drug testing platform that uses a biological and digital solution to model patient cancer environments. Their algorithm precisely predicts drug efficacy, validated by matching clinical outcomes in independent studies. This service helps pharmaceutical developers optimize drug candidates, reduce preclinical bottlenecks, and accelerate time-to-market by focusing resources on therapies with higher predictive efficacy.
Updated 2 months ago
Funding
$220K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
VK
Funding rounds are not available yet.
Founders
Product
Features
- This company provides a tumor-based drug testing platform that uses a biological and digital solution to model patient cancer environments. Their algorithm precisely predicts drug efficacy, validated by matching clinical outcomes in independent studies. This service helps pharmaceutical developers optimize drug candidates, reduce preclinical bottlenecks, and accelerate time-to-market by focusing resources on therapies with higher predictive efficacy.